Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Best Overall Tumor Response

Outcome Time Frame:

every other 21 day cycle (6-8 cycles), every 3 months during long-term follow-up

Safety Issue:

No

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Investigator Role:

Study Director

Investigator Affiliation:

Eli Lilly and Company

Authority:

Russia: Pharmacological Committee, Ministry of Health

Study ID:

9340

NCT ID:

NCT00191334

Start Date:

December 2004

Completion Date:

December 2007

Related Keywords:

• Ovarian Cancer
• Ovarian Neoplasms